# Morpheus-panBC (NCT03424005)

> A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03424005
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Metastatic Breast Cancer
- Interventions: Capecitabine; Atezolizumab; Ipatasertib; SGN-LIV1A; Bevacizumab; Chemotherapy (Gemcitabine + Carboplatin or Eribulin); Selicrelumab; Tocilizumab; Nab-Paclitaxel; Sacituzumab Govitecan; Abemaciclib; Fulvestrant; Ribociclib (Dose #1); Inavolisib (Dose #1); Trastuzumab Deruxtecan; Ribociclib (Dose #2); Letrozole; Inavolisib (Dose #2); Empagliflozin; Palbociclib; Metformin; Atirmociclib; Giredestrant
- Enrollment: 1132
- Primary outcome: Objective Response Rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=morpheus-panbc-nct03424005